Impact of Baseline Covariates on the Immunogenicity of a Quadrivalent (Types 6, 11, 16, and 18) Human Papillomavirus Virus-Like-Particle Vaccine

• Published in: The Journal of infectious diseases Vol. 196; no. 8; pp. 1153 - 1162
• Main Authors: Giuliano, Anna R., Lazcano-Ponce, Eduardo, Villa, Luisa, Nolan, Terry, Marchant, Colin, Radley, David, Golm, Greg, McCarroll, Kathleen, Yu, Jimmy, Esser, Mark T., Vuocolo, Scott C., Barr, Eliav
• Format: Journal Article
• Language: English
• Published: United States The University of Chicago Press 15.10.2007; University of Chicago Press
• Subjects: Adolescent; Adult; Alphapapillomavirus - classification; Alphapapillomavirus - immunology; Antibodies; Antibody Formation; Child; Cigarette smoking; Double-Blind Method; Female; Human papillomavirus; Human papillomavirus 16; Human papillomavirus 6; Humans; Immune response; Infections; Male; Papillomavirus Infections - immunology; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines - immunology; Placebos; Preventive medicine; Sexually Transmitted Diseases, Viral - immunology; Sexually Transmitted Diseases, Viral - prevention & control; Treatment Outcome; Vaccination; Viruses

Background.The quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle vaccine was 95%–100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18. Vaccine efficacy is thought to be mediated by humoral immunity. Here, we analyze the...